F. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy.
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TO THE EDITOR
Human T cell lymphotropic virus type-1 (HTLV-1), the first human retrovirus to be discovered, causes adult T cell leukemia/lymphoma (ATLL). HTLV-1 infection, like human immunodeficiency virus (HIV) infection, leads to immunodeficiency in the hosts, especially in patients who develop ATLL; ATLL patients are susceptible to opportunistic infections and are at an increased risk of other malignancies. ATLL is an aggressive peripheral T cell neoplasia with unique clinical features such as skin involvement and hypercalcemia. The incidence of ATLL is high in southwestern Japan, particularly in Okinawa.
Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcomaassociated herpesvirus, was first detected in Kaposi's sarcoma (KS) tissues from acquired immunodeficiency syndrome (AIDS) patients. 1 Subsequently, the virus has been associated with all forms of KS (classic, iatrogenic, endemic, and AIDS-associated), primary effusion lymphoma, and a subset of multicentric Castleman's disease. KS is rare in Asia, even in patients with AIDS, but the incidence of KS not associated with HIV infection is high in Okinawa. 2 Although some cases of KS associated with ATLL have been reported, no study has yet been reported describing the increased rate of HHV-8 infection in ATLL patients.
In this study, we measured HHV-8 antibodies in 84 ATLL patients and 264 patients with other hematological diseases in Okinawa between 1990 and 2000 to observe the possible association between HHV-8 infection and ATLL. HHV-8 antibodies in plasma samples were tested by ELISA using the recombinant HHV-8 orf 65.2 protein.
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The mean of optical density of plasma samples obtained from 10 blood donors plus 5 standard deviations was used as a cut-off value. Sera taken from two KS patients and a normal person, used as positive and negative control respectively, were included in each assay. We also studied 200 HTLV-1-positive and 1079 HTLV-1-negative plasma samples collected from general blood donors in the Japanese Red Cross Okinawa Blood Center. Anti-HHV-8 antibodies were positive in two (2.4%) of the 84 ATLL patients (Table 1) : a 59-year-old female of lymphoma type and a 58-year-old female of acute type ATLL, according to Shimoyama classification, 4 showed positive anti-HHV-8 antibodies on ELISA. Both patients were native Okinawans. We also investigated the presence of HHV-8, Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6), HTLV-1 and HIV in peripheral blood mononuclear cells of both patients, using polymerase chain reaction (PCR) techniques. Patient No. 1 was positive for HTLV-1, EBV and HHV-6, but negative for HHV-8, while patient No. 2 was positive for HTLV-1, HHV-8 and EBV, but negative for HHV-6 (Figure 1 ). Neither of them was positive for HIV (data not shown). Despite combination chemotherapy (cyclophosphamide, adriamycin, vincristine, prednisolone, bleomycin, and etoposide), they expired due to disease progression without symptoms related to these herpesviruses.
Anti-HHV-8 antibodies were found in two of 264 patients with other hematological diseases: a 86-year-old HTLV-1-positive female with myelodysplastic syndrome and a 71-year-old HTLV-1-negative male with non-Hodgkin's lymphoma. In general blood donors, anti-HHV-8 antibodies were detected in one (0.5%) of 200 HTLV-1-positive persons and one (0.1%) of 1079 HTLV-1-negative persons. The rate of HHV-8 infection in ATLL patients was significantly higher than in the general blood donors (P ϭ 0.01, Fisher's exact probability test), indicating an increased risk of HHV-8 infection in patients with ATLL.
In summary, we conclude that the prevalence of anti-HHV-8 antibodies in patients with ATLL is higher than in other populations and multiple viral infections observed in two ATLL patients, may be explained by the functional impairment of T cells. According to Nakamura et al, 5 CD4-positive lymphocytes, infected with HIV or HTLV-1, secrete a potential mitogen which stimulates the growth of KS. Thus, our present findings suggest an increased risk of KS in patients with ATLL. to defects further downstream in the apoptotic pathway. Van den Berg et al 7 suggested that thermolability of the receptor-ligand complex might be a cause of GC resistance. In refractory and fully resistant murine cell lines non-saturating, low affinity binding of steroid occurred when assayed at 37°C. However, when assayed at room temperature, the intracellular receptors were found to be in a stablebinding, high affinity configuration, masking differences between resistant and sensitive cell lines. This mechanism of resistance would easily escape attention as routine tests are usually performed at room temperature.
In this study we studied GR expression levels and affinities for dexamethasone (DXM) at both room temperature and 37°C in pediatric ALL and AML samples and correlated these data with in vitro GC resistance.
Bone marrow or peripheral blood samples taken for routine diagnostic procedures were obtained from 37 ALL and 10 AML patients at initial diagnosis with informed consent. GR expression and affinity (dissociation constant) for DXM were determined by ligand binding assay as described by Costlow et al, 8 with minor modifications and Scatchard plot analysis of the data. The efflux period necessary for
